PSA Screening

Home » PSA Screening

New Study Offers Support for Prostate Testing

For men who are weighing the pros and cons of prostate cancer screening, a new study strengthens the evidence that testing can reduce deaths from this cancer, something two earlier large landmark clinical trials appeared to reach different conclusions about. Read the article here.

New IsoPSA assay detects prostate cancer more precisely than current tests

A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease. Read the article here.

Video: “The Prostate Gland and Testosterone: relationship, importance to overall health, and the impact of prostate cancer and treatment on one’s health”

March 2017 Awareness Night The Prostate Gland and Testosterone: relationship, importance to overall health, and the impact of prostate cancer and treatment on one’s health Dr. Joseph R. LaBossiere, BMSc, MD, MSc, FRCSC Reconstructive Urology Fellow, Sunnybrook Health Sciences Centre             CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 58:43 minutes

Video: “The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment”

January 2017 Awareness Night The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment Dr. Raj Satkunasivam, MD, MS, FRCSC Urologic Oncologist,  Odette Cancer Centre, Sunnybrook Health Sciences Centre Assistant Professor, Division of Urology, Department of Surgery, University of Toronto     CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 40:51 minutes

Prostate Multiparametric MRI Feasible for PCa Screening

Robert K. Nam, MD, from the Sunnybrook Health Sciences Center in Toronto, and colleagues examined the feasibility of prostate MRI as the primary screening test for prostate cancer in a cohort of unselected men from the general population. All participants underwent prostate multiparametric MRI and random or targeted biopsies as well as prostate-specific antigen testing. Initial results showed that prostate MRI was better to predict prostate cancer than PSA. Read the article here.

New prostate cancer test strives to slash biopsies

Because PSA is secreted both by normal cells and cancer cells, its levels could be high for other reasons and not necessarily cancer: age, an inflammation of the prostate gland, or even a bicycle ride. But most often when doctors receive a high reading, they send their patients to do a biopsy, just to be on the safe side. Cleveland Diagnostics is developing a technology and test kit that can identify the PSA that specifically comes from cancer cells. Read the article here.

Scroll to Top